Silverback Therapeutics Quote - SBTX

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

5.87

Bid

2.37

Offer

6.15

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

563.502M

Previous Close

5.87

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

95,997,000

Dividend Yield

PE Ratio

-19.76

Earnings Per Share (EPS)

-0.57

Revenue

30k

Net Profit

-54.37M

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ars-pharma.com

Headquarters

Wilmington, Delaware, USA

Founded

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy, Asthma and Immunology Annual Meeting Data Support New Drug Application for neffy®, Currently Under Review...

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug...

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under...

Silverback Therapeutics' Nasal Spray for Allergic Reactions Gets FDA Review Approval

By Sabela Ojea Silverback Therapeutics Inc. said Friday that the U.S. Food and Drug Administration has accepted for review its new drug application for Neffy, an emergency nasal spray to treat...

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved Silverback Therapeutics, Inc. (Nasdaq:...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

SBTX - Frequently Asked Questions (FAQ)

What is the current Silverback Therapeutics share price?

The current share price of Silverback Therapeutics is US$ 5.87

How many Silverback Therapeutics shares are in issue?

Silverback Therapeutics has 95,997,000 shares in issue

What is the market cap of Silverback Therapeutics?

The market capitalisation of Silverback Therapeutics is USD 563.5M

What is the 1 year trading range for Silverback Therapeutics share price?

Silverback Therapeutics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Silverback Therapeutics?

The price to earnings ratio of Silverback Therapeutics is -19.76

What is the cash to sales ratio of Silverback Therapeutics?

The cash to sales ratio of Silverback Therapeutics is 37.3k

What is the reporting currency for Silverback Therapeutics?

Silverback Therapeutics reports financial results in USD

What is the latest annual turnover for Silverback Therapeutics?

The latest annual turnover of Silverback Therapeutics is USD 30k

What is the latest annual profit for Silverback Therapeutics?

The latest annual profit of Silverback Therapeutics is USD -54.37M

What is the registered address of Silverback Therapeutics?

The registered address for Silverback Therapeutics is 108 W. 13TH STREET, SUITE 100, WILMINGTON, DELAWARE, 19801

What is the Silverback Therapeutics website address?

The website address for Silverback Therapeutics is ars-pharma.com

Which industry sector does Silverback Therapeutics operate in?

Silverback Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
FCUVFocus Universal Inc	US$ 0.9499 (174.93%)	259.78M
NITON2OFF Inc	US$ 2.6306 (145.85%)	350.92M
CRNCCerence Inc	US$ 19.33 (143.76%)	159.55M
KITTNauticus Robotics Inc	US$ 3.8249 (140.56%)	104.78M
ACONAclarion Inc	US$ 0.2984 (110.14%)	305.59M
HWHHWH International Inc	US$ 0.4621 (-28.80%)	7.08M
SMSTDefiance Daily Target 2x Short MSTR ETF	US$ 5.69 (-26.30%)	24.62M
RAINRain Enhancement Technologies Holdco Inc	US$ 5.59 (-23.42%)	155.16k
PTLEPTL Ltd	US$ 9.35 (-23.30%)	967.95k
NXUNXU Inc	US$ 0.725868 (-22.78%)	7.4M
NITON2OFF Inc	US$ 2.6306 (145.85%)	358.28M
TGLTreasure Global Inc	US$ 0.382 (101.58%)	337.5M
ACONAclarion Inc	US$ 0.2984 (110.14%)	305.64M
FCUVFocus Universal Inc	US$ 0.9499 (174.93%)	260.93M
NVDANVIDIA Corporation	US$ 144.47 (4.45%)	230.01M